Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Netflix
NFLX
|
+$385M |
| 2 |
Microsoft
MSFT
|
+$368M |
| 3 |
Berkshire Hathaway Class A
BRK.A
|
+$298M |
| 4 |
Delta Air Lines
DAL
|
+$208M |
| 5 |
Carnival Corporation Ltd
CCL
|
+$203M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$1.34B |
| 2 |
Tesla
TSLA
|
+$353M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$303M |
| 4 |
NVIDIA
NVDA
|
+$290M |
| 5 |
Boeing
BA
|
+$286M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.37% |
| 2 | Healthcare | 18.47% |
| 3 | Consumer Discretionary | 12.41% |
| 4 | Consumer Staples | 10.13% |
| 5 | Industrials | 9.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3151
Evolus
EOLS
$530M
| $154K | ﹤0.01% |
16,900
-146,000
| -90% | -$1.31M |
|
3152
Gain Therapeutics
GANX
$92.1M
| $154K | ﹤0.01% |
46,900
-700
| -1% | -$2.65K |
|
|
VIRX
3153
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $154K | ﹤0.01% |
148,199
+13,400
| +10% | +$18.2K |
|
3154
GDS Holdings
GDS
$6.97B
| $153K | ﹤0.01% |
14,000
-3,000
| -18% | -$34.3K |
|
3155
Data Storage Corp
DTST
$8.37M
| $150K | ﹤0.01% |
46,258
-4,143
| -8% | -$12.1K |
|
3156
American Shared Hospital Services
AMS
$10.6M
| $148K | ﹤0.01% |
59,988
-14,807
| -20% | -$38.6K |
|
3157
Creative Realities
CREX
$44M
| $148K | ﹤0.01% |
95,503
+13,300
| +16% | +$33.5K |
|
3158
Daxor
DXR
$60.7M
| $148K | ﹤0.01% |
15,821
+500
| +3% | +$4.85K |
|
|
DMRA
3159
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.9B
| $148K | ﹤0.01% |
8,204
+1,570
| +24% | +$61.6K |
|
|
STRR
3160
DELISTED
Star Equity Holdings
STRR
| $148K | ﹤0.01% |
30,300
+16,426
| +118% | +$83.4K |
|
3161
Trevi Therapeutics
TRVI
$2.56B
| $147K | ﹤0.01% |
67,300
-22,000
| -25% | -$49.7K |
|
3162
Biote Corp
BTMD
$42.7M
| $146K | ﹤0.01% |
28,577
-41,844
| -59% | -$247K |
|
3163
Capricor Therapeutics
CAPR
$244M
| $146K | ﹤0.01% |
42,621
-3,800
| -8% | -$21.4K |
|
|
SNCE
3164
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $146K | ﹤0.01% |
18,279
-13,986
| -43% | -$83.1K |
|
|
CMCT
3165
Creative Media & Community Trust
CMCT
$15M
| $145K | ﹤0.01% |
1
-1
| -50% | -$108K |
|
3166
Crexendo
CXDO
$217M
| $145K | ﹤0.01% |
68,704
+9,004
| +15% | +$16.5K |
|
|
JFIN
3167
Jiayin Group
JFIN
$120M
| $143K | ﹤0.01% |
+26,600
| New | +$151K |
|
|
HLTH
3168
DELISTED
Cue Health Inc. Common Stock
HLTH
| $143K | ﹤0.01% |
323,800
-61,100
| -16% | -$27.9K |
|
3169
Fathom Holdings
FTHM
$24.5M
| $142K | ﹤0.01% |
34,700
-200
| -0.6% | -$1.3K |
|
3170
Beyond Air
XAIR
$6.2M
| $142K | ﹤0.01% |
+154
| New | +$202K |
|
3171
Katapult Holdings
KPLT
$35.9M
| $141K | ﹤0.01% |
13,797
+161
| +1% | +$2.56K |
|
|
RENT
3172
Rent the Runway
RENT
$122M
| $141K | ﹤0.01% |
10,390
-325
| -3% | -$9.26K |
|
3173
Scienjoy Holding
SJ
$36.9M
| $141K | ﹤0.01% |
50,300
-9,400
| -16% | -$28.7K |
|
3174
Atomera
ATOM
$212M
| $140K | ﹤0.01% |
+22,400
| New | +$160K |
|
3175
Turkcell
TKC
$4.72B
| $139K | ﹤0.01% |
29,300
-114,956
| -80% | -$548K |
|
Similar funds
Jim Simons's Q3 2023 Portfolio in Review
As of Q3 2023, Jim Simons held 4,329 positions worth $58.7B, down 15% from $69.4B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Jim Simons withdrew a net $8.34B in Q3 2023, closing 713 positions and reducing 1,794 holdings. Its most notable exit was Chevron, an estimated $185M position sold in full.
By sector, the portfolio is most concentrated in Technology at 19% of assets, down from 20% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Jim Simons opened a new position in D.R. Horton worth $125M.
- Jim Simons's largest Q3 2023 buy was D.R. Horton: 1,159,438 shares worth $125M.
- Jim Simons added most to Netflix in Q3 2023, an estimated $385M increase.
- Jim Simons's biggest Q3 2023 reduction was Meta Platforms (Facebook), cutting an estimated $1.34B.
- Jim Simons fully exited Chevron in Q3 2023, selling an estimated $185M.
- Jim Simons's ten largest holdings make up 12% of its $58.7B portfolio in Q3 2023.
- Jim Simons opened 464 new positions and closed 713 in Q3 2023.
- Jim Simons's portfolio value fell 15% quarter-over-quarter to $58.7B.
Based on Renaissance Technologies's 13F filing for Q3 2023, filed 14 Nov 2023.